...your health first  
THERAPEUTIC AREAS  print
Sinerga

WHAT IT IS
It is a product indicated for the prevention of Recurrent Respiratory Infections (RRI) based on a new therapeutic concept, which essentially changes the point of approach of conventional therapies in the prevention of RRI.
It has been recently discovered that Recurrent Respiratory Infections (RRI) occur in people who, as a result of exposure to some enhancing and/or predisposing factors (depression conducted by viral infections on the immune system, immunological virginity, relative immaturity of the immune system, change in temperature, etc..) manifest a minimum persistent inflammation against the respiratory mucosa. This minimum persistent inflammation, leads to a remodeling of the respiratory mucosa which facilitates the adhesion of respiratory viruses before and bacterial pathogens after. The adhesion of these pathogens determines the inflammation and the alimentation of the inflammatory process.
Sinerga exerts its action by significantly reducing the condition of minimum persistent inflammation against the respiratory mucosa and consequently its remodeling, which is the key point of initiation of the vicious circle of Recurrent Respiratory Infections (RRI).
WHEN TO USE
In subjects exposed to factors predisposing and/or favoring RRI, who during the winter suffer from more than 5-6 episodes of respiratory infections.
The product can also be used in the acute phase, that is during the event of a respiratory infection, in addition to drug therapy.
HOW TO USE
Pediatric age (3-12 years old)
- 1 liquid-dispersible sachet a day
Adults (age > 12 years old)
- 2 liquid-dispersible sachets a day
The assumption of the contents of the liquid-dispersible sachets must be made preferably on an empty stomach, at least 15 minutes before meals, preferably in the morning or evening (for once daily dosing it is preferable to take the contents of the sachet in the morning).
Supplementation with SINERGA in susceptible individuals or in the course of Respiratory Infections (RI) and Recurrent Respiratory Infections (RRI), is recommended for 10 consecutive days per month, to be repeated for at least 4 consecutive months. The first month of treatment, therapy should be extended up to 20 days.
Supplementation with SINERGA is also indicated in conjunction with a possible antibiotic treatment.
Pour the contents of the sachet into a glass (preferably plastic), add the thickness of two inches of water, mix thoroughly and swallow.
HOW IT WORKS
Sinerga produces two key actions in the prevention of Recurrent Respiratory Infections (RRI), the first aimed at reducing the minimum persistent inflammatory condition against the respiratory mucosa, and the second aimed at carrying in a direct and indirect way some antibodies, that is IgA and IgG.
The reduction of the minimum persistent inflammatory condition is carried out by palmitoylethanolamide, a fatty acid amide able to raise the threshold of mast cell degranulation, that is to reduce the constant production of chemical mediators of inflammation that lead to a remodeling of the epithelium of the respiratory mucosa, responsible for the easy adhesion and penetration in the organism of respiratory viruses and pathogenic bacteria.
The direct and indirect contribution of IgA and IgG is determined by two components of the product, that is by the Kluyveromyces F.M B0399 lactic yeast and the colostrum. The first stimulates the production of endogenous IgA and the second carries a significant amount of exogenous IgG.
WHAT ARE THE EXPECTED BENEFITS
Reduction of the number of episodes of respiratory infections, especially during the winter, and significant reduction of the intake of antibiotics and anti-inflammatory drugs.
WHAT ARE THE ADVANTAGES OVER THE TRADITIONAL THERAPIES
Through its radically innovative approach to therapy ever introduced before, Sinerga eliminates the main cause of Recurrent Respiratory Infections (RRI), represented by the minimum persistent inflammatory condition against the respiratory mucosa, without underestimating the integrity and efficiency of the immune system through a direct and indirect contribution of IgA and IgG.

 

  Sinerga Preview EN

Promozione Galsor Video Galsor
Master VAS 2015
Miti’ da sfatare e ‘raccomandazioni’ da conoscere
Il Master si articola in Corsi Teorico-Pratici, Letture Magistrali e Tavole Rotonde e ‘Quadra...Read more
GALSOR LANCIA DUE NUOVI PRODOTTI
SINUMER E IPERNASEFLU